Patents by Inventor Tanja Schulz-Gasch

Tanja Schulz-Gasch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190248803
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 15, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Olivier GAVELLE, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Didier Rombach, Tanja Schulz-Gasch
  • Patent number: 10308659
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: June 4, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Olivier Gavelle, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Roever Stephan, Mark Rogers-Evans, Didier Rombach, Tanja Schulz-Gasch
  • Patent number: 9827244
    Abstract: The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: November 28, 2017
    Assignees: F. Hoffmann-La Roche AG, Savira pharmaceuticals GmbH, European Molecular Biology Laboratory
    Inventors: Tanja Schulz-Gasch, Robert Weikert, Werner Neidhart, Helmut Buschmann, Oliver Szolar, Andrea Wolkerstorfer, Norbert Handler, Franz-Ferdinand Roch, Stephen Cusack
  • Patent number: 9694012
    Abstract: The invention relates to a compound of formula (I) wherein A1 to A3 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: July 4, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Fabienne Ricklin, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • Publication number: 20170100396
    Abstract: The present invention relates to a compound having the general formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, codrug, cocrystal, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing influenza. Furthermore, specific combination therapies are disclosed.
    Type: Application
    Filed: October 5, 2016
    Publication date: April 13, 2017
    Inventors: Tanja SCHULZ-GASCH, Robert WEIKERT, Werner NEIDHART, Andrea WOLKERSTORFER, Oliver SZOLAR, Norbert HANDLER, Helmut BUSCHMANN, Stephen CUSACK
  • Publication number: 20170081331
    Abstract: The present invention relates to a compound having the general formula (IIa) or (IIb), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Application
    Filed: September 15, 2016
    Publication date: March 23, 2017
    Inventors: Helmut BUSCHMANN, Oliver SZOLAR, Andrea WOLKERSTORFER, Norbert HANDLER, Franz-Ferdinand ROCH, Stephen CUSACK, Robert WEIKERT, Werner NEIDHART, Tanja SCHULZ-GASCH
  • Patent number: 9580435
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: February 28, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • Publication number: 20170035769
    Abstract: The invention relates to a compound of formula (I) wherein A1 to A3 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: October 24, 2016
    Publication date: February 9, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: UWE GRETHER, ATSUSHI KIMBARA, MATTHIAS NETTEKOVEN, FABIENNE RICKLIN, STEPHAN ROEVER, MARK ROGERS-EVANS, TANJA SCHULZ-GASCH
  • Publication number: 20170000788
    Abstract: The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Application
    Filed: June 1, 2016
    Publication date: January 5, 2017
    Inventors: Tanja Schulz-Gasch, Robert Weikert, Werner Neidhart, Helmut Buschmann, Oliver Szolar, Andrea Wolkerstorfer, Norbert Handler, Franz-Ferdinand Roch, Stephen Cusack
  • Patent number: 9522886
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: December 20, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Beat Frei, Luca Gobbi, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • Patent number: 9512132
    Abstract: The invention relates to a compound of formula (I) wherein A1 to A3 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: December 6, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Uwe Grether, Atsushi Kimbara, Nettekoven Matthias, Ricklin Fabienne, Roever Stephan, Mark Rogers-Evans, Tanja Schulz-Gasch
  • Patent number: 9512141
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) is a CB2 receptor agonist for use in the treatment of several disorders, such as pain, atherosclerosis and glaucoma.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: December 6, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Baledi Dhurwasulu, Uwe Grether, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • Patent number: 9505762
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: November 29, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Stefanie Bendels, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • Patent number: 9464098
    Abstract: The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are LMP7 inhibitors and may be useful in treating associated inflammatory diseases and disorders such as, for example, rheumatoid arthritis, lupus and irritable bowel disease.
    Type: Grant
    Filed: November 29, 2013
    Date of Patent: October 11, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Stephen M. Lynch, Werner Neidhart, Jean-Marc Plancher, Tanja Schulz-Gasch
  • Patent number: 9409866
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) is a CB2 agonist and can be used as an active ingredient in a medicament.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: August 9, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Fabienne Ricklin, Stephan Roever, Mark Rogers-Evans, Didier Rombach, Tanja Schulz-Gasch, Matthias Westphal
  • Patent number: 9359351
    Abstract: The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: June 7, 2016
    Assignees: F. Hoffmann-La Roche AG, Savira pharmaceuticals GmbH, European Molecular Biology Laboratory
    Inventors: Tanja Schulz-Gasch, Robert Weikert, Werner Neidhart, Helmut Buschmann, Oliver Szolar, Andrea Wolkerstorfer, Norbert Handler, Franz-Ferdinand Roch, Stephen Cusack
  • Publication number: 20160137606
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: January 21, 2016
    Publication date: May 19, 2016
    Inventors: Caterina Bissantz, Uwe Grether, Paul Hebeisen, Atsushi Kimbara, Qingping Liu, Matthias Nettekoven, Marco Prunotto, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch, Christoph Ullmer, Zhiwei Wang, Wulun Yang
  • Patent number: 9321727
    Abstract: The invention relates to a compound of formula (I) Wherein R1, R2, R3 and R4 are defined as in the description and in the claims. The said compounds of the invention are preferential agoniste of the Carsonabinocid Receptor 2 and thus useful as medicaments and may be used in treatment of chronic pain, atherosclerosis, ischemic/reperfusion injury and other related diseases. A representative compound of this invention is 6-cyclopropylmethoxy-5-(tetrahydro-pyradine-2-carboxglic acid [1-methyl-1-(5-methyl-(1,2,4]oxadiazol-3-yl)-ethyl)-amide.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: April 26, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Caterina Bissantz, Uwe Grether, Paul Hebeisen, Atsushi Kimbara, Qingping Liu, Matthias Nettekoven, Marco Prunotto, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch, Christoph Ullmer, Zhiwei Wang, Wulun Yang
  • Patent number: 9303012
    Abstract: The invention relates to CB2 agonists of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: April 5, 2016
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Stefanie Bendels, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Ernst Schaffter, Tanja Schulz-Gasch
  • Publication number: 20160083357
    Abstract: The invention relates to a compound of formula (I) wherein R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 4, 2015
    Publication date: March 24, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Uwe Grether, Matthias Nettekoven, Bernd Puellmann, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch